Knopp Biosciences We Are a Biotechnology Company Seeking to Improve Patients’ Lives

Discovering, Developing, and Delivering Breakthrough Medications

Scroll to discover
For Healthcare Professionals

Live Changing Medicine

Discovering, Developing, and Delivering Breakthrough Medications

Discover our current investigational platforms:

Dexpramipexole

An Uncommon Approach to Severe Asthma

  • In development for patients with moderate-to-severe eosinophilic asthma
  • 50% of asthma patients have increased levels of inflammatory eosinophils

Drugs approved for eosinophilic asthma must be injected or infused. Knopp is developing an oral medication for eosinophilic asthma.

Kv7

Focused on Research to Help Young Lives

  • A precision medicine approach to developmental and epileptic encephalopathy
  • Our lead investigational program targets Kv7 research in a rare disease in newborns called KCNQ2 epileptic encephalopathy (KCNQ2-EE)

We direct our discovery research to genetically defined diseases caused by Kv7 channel dysfunction

Knopp Biosciences

A Biotechnology Company Seeking to Save Lives
  • Neurological Diseases
  • Immunological Conditions